Earnings summaries and quarterly performance for NEKTAR THERAPEUTICS.
Executive leadership at NEKTAR THERAPEUTICS.
Board of directors at NEKTAR THERAPEUTICS.
Research analysts who have asked questions during NEKTAR THERAPEUTICS earnings calls.
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for NKTR
Also covers: ALKS, ALNY, AMRN +23 more
Mayank Mamtani
B. Riley Securities
3 questions for NKTR
Also covers: AGEN, ALT, ARWR +18 more
YR
Yasmeen Rahimi
Piper Sandler & Co.
3 questions for NKTR
Also covers: ALT, ARCT, CRNX +12 more
AH
Arthur He
H.C. Wainwright & Co.
2 questions for NKTR
Also covers: ADAP, AUPH, HOOK +1 more
Jay Olson
Oppenheimer & Co. Inc.
2 questions for NKTR
Also covers: ACAD, AMGN, BIIB +22 more
AR
Alexandra Ramsey
William Blair & Company, L.L.C.
1 question for NKTR
Also covers: VKTX
AH
Andy Hsieh
William Blair & Company
1 question for NKTR
Also covers: ALT, BYSI, CRDF +8 more
Cha Cha Yang
Jefferies
1 question for NKTR
Also covers: TGTX
Cheng Li
Oppenheimer & Co. Inc.
1 question for NKTR
Also covers: EDIT, EXEL, INO +3 more
DR
Dominic Risso-Gill
TD Cowen
1 question for NKTR
Also covers: ALT
Eric Joseph
JPMorgan Chase & Co.
1 question for NKTR
Also covers: BEAM, BLUE, ENTA +9 more
JS
Jiale Song
Jefferies Financial Group Inc.
1 question for NKTR
Also covers: ACRS, CRVS, CTMX +12 more
RS
Roger Song
Jefferies
1 question for NKTR
Also covers: AADI, AKBA, ALT +13 more
TH
Tsan-Yu Hsieh
William Blair & Company
1 question for NKTR
Also covers: AVIR, CRDF, EXEL +6 more
Yu He
H.C. Wainwright & Co., LLC
1 question for NKTR
Also covers: ADAP, BCAB
YH
Yu He (Arthur)
H.C. Wainwright & Co., LLC
1 question for NKTR
Also covers: ALXO, AUPH
Recent press releases and 8-K filings for NKTR.
Nektar Therapeutics Announces Positive Phase 2b REZOLVE-AA Trial Results for Rezpegaldesleukin
NKTR
New Projects/Investments
- Nektar Therapeutics announced positive topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA trial for rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
- The primary endpoint showed a mean percent reduction in SALT score at Week 36 of 28.2% for the 24 µg/kg arm and 30.3% for the 18 µg/kg arm, compared to 11.2% for placebo.
- When excluding four patients with major study eligibility violations, both treatment arms achieved statistical significance, with mean percent SALT reductions of 29.6% (24 µg/kg) and 30.4% (18 µg/kg) versus 5.7% for placebo.
- The drug demonstrated a favorable safety and tolerability profile, with a low discontinuation rate due to adverse events of 1.4% in the combined treatment arms.
- These results establish the Phase 3 dose (24 µg/kg) and support the planned advancement to Phase 3 development for alopecia areata in 2026.
Dec 16, 2025, 1:00 PM
Nektar Therapeutics Reports Positive Phase 2 Results for Rezpegaldesleukin in Alopecia Areata
NKTR
New Projects/Investments
- Nektar Therapeutics announced positive top-line results from its Phase 2 Resolve AA study for rezpegaldesleukin (Respike) in severe to very severe alopecia areata.
- The study achieved its target product profile, demonstrating comparable efficacy to a low-dose JAK inhibitor and a favorable, differentiated safety profile that does not require extensive laboratory testing or monitoring, addressing a significant unmet medical need.
- Rezpegaldesleukin 24 micrograms per kilogram was identified as the optimal dose for Phase 3 advancement, with a planned 52-week induction period for the registrational program.
- These results establish proof-of-concept for rezpegaldesleukin as a first-in-class biologic for alopecia areata, providing a strong basis to advance into Phase 3 development.
Dec 16, 2025, 1:00 PM
Nektar Therapeutics Announces Topline Phase 2b REZOLVE-AA Trial Results for Rezpegaldesleukin
NKTR
New Projects/Investments
- Nektar Therapeutics announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial for investigational rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
- The primary endpoint, mean percent reduction in SALT score at Week 36, was 28.2% for the 24 µg/kg arm and 30.3% for the 18 µg/kg arm, compared to 11.2% for placebo, narrowly missing statistical significance.
- When excluding four patients with major study eligibility violations, both rezpegaldesleukin treatment arms met statistical significance (p=0.049 and p=0.042), showing mean percent SALT reductions of 29.6% and 30.4% versus 5.7% for placebo.
- Rezpegaldesleukin was well tolerated with a safety profile consistent with previously reported results, and the company plans to advance it to Phase 3 development in alopecia areata in 2026.
Dec 16, 2025, 12:30 PM
Nektar to Host Conference Call for REZOLVE-AA Phase 2b Study Results
NKTR
New Projects/Investments
- Nektar Therapeutics (Nasdaq: NKTR) will host an investor call and live webcast on December 16, 2025, at 8:00 am ET.
- The event will review topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA clinical trial.
- This trial is evaluating investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.
- The results will be provided in a morning press release and presented during the webcast, which will also have a replay available for at least 30 days.
Dec 15, 2025, 11:00 PM
Nektar Therapeutics Provides Pipeline Update on Alopecia Areata and Atopic Dermatitis Programs
NKTR
New Projects/Investments
Guidance Update
- Nektar Therapeutics expects to read out Phase 2b data for its alopecia areata (AA) program, RESPECT, next month (December 2025). The study enrolled patients with severe to very severe AA, benchmarking against low-dose Xeljanz/Olumiant.
- The company aims for rezpegaldesleukin to be the first biologic approved in AA, highlighting its potential safety advantage over JAK inhibitors, which carry black box warnings and numerous risk factors. Market research indicates a strong preference for biologics due to safety and convenience.
- For atopic dermatitis (AD), Nektar will read out 52-week maintenance data from its Phase 2b study in Q1 2026. The program has shown a differentiating feature by reducing ACQ5 scores in AD patients with comorbid asthma, a capability shared by only two other drugs (JAK inhibitors and Dupixent).
- An end-of-Phase 2 meeting with the FDA is planned before year-end to discuss the Phase 3 design for AA. If positive, AA could launch 12-18 months after AD, creating a substantial opportunity with two indications.
Nov 20, 2025, 11:00 AM
Nektar Therapeutics Provides Pipeline Updates for Alopecia Areata and Atopic Dermatitis
NKTR
New Projects/Investments
Guidance Update
- Nektar Therapeutics expects to read out Phase 2b data for rezpegaldesleukin in alopecia areata (AA) next month (December 2025), with the primary endpoint being the % change from baseline in SALT. The company aims to benchmark against low-dose Xeljanz efficacy while offering a superior safety profile as a potential first biologic in AA.
- Market research indicates a strong preference among dermatologists and patients for a biologic with rezpegaldesleukin's profile over JAK inhibitors for AA, citing safety advantages and convenience, which could significantly expand the addressable market.
- The company anticipates reading out 52-week maintenance data from its Phase 2b atopic dermatitis (AD) study in Q1 2026, evaluating once-a-month and once-every-three-month dosing regimens and the deepening of responses.
- Recent data for rezpegaldesleukin in AD patients with comorbid asthma demonstrated a reduction in ACQ5 scores, a differentiating feature compared to selective IL-13 inhibitors, suggesting broader therapeutic potential in TH2-mediated diseases.
- An end-of-Phase 2 meeting with the FDA is planned before the end of 2025 to discuss the Phase 3 design and overall Biologics License Application (BLA) plan for rezpegaldesleukin.
Nov 20, 2025, 11:00 AM
Nektar Therapeutics Provides Updates on Alopecia Areata and Atopic Dermatitis Programs
NKTR
New Projects/Investments
Guidance Update
- Nektar Therapeutics anticipates top-line Phase 2b data for rezpegaldesleukin in alopecia areata (AA) next month (December 2025), targeting a 20%-25% placebo-adjusted SALT reduction as a benchmark against low-dose Xeljanz.
- Rezpegaldesleukin is positioned as a potential first biologic for AA, offering a differentiated safety profile compared to JAK inhibitors, which could significantly expand the market.
- For atopic dermatitis (AD), Nektar will release 52-week maintenance data from its Phase 2b study in Q1 2026, following recent data showing rezpegaldesleukin's ability to reduce ACQ5 scores in AD patients with comorbid asthma.
- An end-of-Phase 2 meeting with the FDA is planned before the end of 2025 for the AD program, with the potential to launch a second indication (AA) 12-18 months after AD if Phase 2 AA results are positive.
Nov 20, 2025, 11:00 AM
Nektar Therapeutics Presents Positive Phase 2b REZOLVE-AD Data for Rezpegaldesleukin
NKTR
New Projects/Investments
- Nektar Therapeutics reported new data from its Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin in moderate-to-severe atopic dermatitis, presented on November 8, 2025.
- The study demonstrated statistically significant and clinically meaningful improvements in mean ACQ-5 scores at week 16 versus placebo in patients with atopic dermatitis and a history of asthma, with two dose arms (24 µg/kg q2w and 24 µg/kg q4w) achieving statistical significance.
- Data from placebo patients who crossed over to receive high-dose rezpegaldesleukin (24 µg/kg q2w) showed an EASI-75 response rate of 60% and an EASI-90 response rate of 37% at week 24, supporting a 24-week induction period for planned Phase 3 studies.
- The company anticipates long-term maintenance data from REZOLVE-AD in Q1 2026 and top-line Phase 2b data for rezpegaldesleukin in alopecia areata in December 2025.
Nov 10, 2025, 11:31 AM
Nektar Therapeutics Presents Positive Phase 2b Data for Rezpegaldesleukin in Atopic Dermatitis
NKTR
New Projects/Investments
Product Launch
- Nektar Therapeutics presented new data from its REZOLVE-AD Phase 2b study for rezpegaldesleukin, demonstrating statistically significant and clinically meaningful improvements in mean ACQ-5 scores at week 16 versus placebo in atopic dermatitis patients with comorbid asthma.
- The data supports advancing the rezpegaldesleukin 24 µg/kg q2w dose regimen with a 24-week induction period into planned Phase 3 studies for atopic dermatitis.
- Upcoming catalysts include top-line Phase 2b data for rezpegaldesleukin in alopecia areata in December 2025 and long-term maintenance data from the REZOLVE-AD study in Q1 2026.
- Rezpegaldesleukin has received Fast Track designation from the FDA for moderate-to-severe atopic dermatitis (February 2025) and severe alopecia areata (July 2025).
Nov 8, 2025, 10:45 PM
Nektar Therapeutics Reports Q3 2025 Financials, Updates Cash Runway, and Anticipates Key Clinical Data Readouts
NKTR
Guidance Update
New Projects/Investments
Management Change
- Nektar Therapeutics ended Q3 2025 with $270.2 million in cash and investments and no debt, extending its cash runway into Q2 2027. The company updated its year-end cash and investments guidance to approximately $240 million, up from a prior range of $100-$185 million.
- Top-line results from the Phase 2b resolved AA study for REZPEG in severe to very severe alopecia areata, which enrolled approximately 90 patients, are expected in December 2025.
- The company is preparing to advance its lead program, REZPEG, into Phase 3 development for moderate to severe atopic dermatitis, with an end-of-phase 2 meeting with the FDA anticipated before the end of 2025.
- Dr. Mary Tagliaferri has rejoined Nektar Therapeutics as Chief Medical Officer.
Nov 6, 2025, 10:00 PM
Quarterly earnings call transcripts for NEKTAR THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more